治疗结膜炎的新喹诺酮类药物贝西沙星  

Besifloxacin: a new fluoroquinolone drug for the treatment of conjunctivitis

作　　者：郗砚彬[1] 张宇[1] 杨丽钦[1] 寇同欣[1] 

机构地区：[1]北京双鹤药业股份有限公司双鹤研究院,北京100102

出　　处：《中国新药杂志》2010年第4期267-269,共3页Chinese Journal of New Drugs

摘　　要：贝西沙星是一种治疗细菌性结膜炎的广谱抗菌剂。与其他喹诺酮类药物相比,其对易引发结膜炎的G+菌和G-菌、厌氧菌具有等效或较强的抗菌作用,对于某些对喹诺酮类药物产生耐药性的菌种,同样具有抗菌作用。同时,贝西沙星通过抑制眼部致炎因子的表达,进行免疫调节,从而更好地发挥其抗菌作用。贝西沙星滴眼后能迅速进入眼部各组织,且具有较长的药效时间。文中对贝西沙星的药理作用、药动学及临床试验进展进行综述。Objective：Besifloxacin is a topical ophthalmic agent with broad antibacterial spectrum for the treatment of bacterial conjunctivitis.Besifloxacin is generally equivalent to or better than other fluoroquinolones in activity against most gram-positive and gram-negative pathogens,and anaerobes.Besifloxacin is active against drug-resistant bacteria to fluoroquinolones.Besifloxacin also inhibits pro-inflammatory cytokines in human with bacterial conjunctivitis.In pharmacokinetic studies,besifloxacin can rapidly penetrate into ocular tissues and is sustained in a long time after a single topical dose of besifloxacin ophthalmic suspension.Recent progress in bioactivity,pharmacokinetics,and study of besifloxacin was briefly reviewed in this paper.

关 键 词：贝西沙星 药理作用 细菌性结膜炎 药动学 临床试验 

分 类 号：R978.19[医药卫生—药品]